Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02316834 · ClinicalTrials.gov registry record · Early Phase 1
Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Early Phase 1 study of Fallopian Tube Serous Adenocarcinoma and High Grade Ovarian Serous Adenocarcinoma, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 4
- Enrollment target
- 6
- Study locations
NCT02316834 is a Early Phase 1 study of Fallopian Tube Serous Adenocarcinoma and High Grade Ovarian Serous Adenocarcinoma that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 4 participants, below the 541-participant average among 8 other Fallopian Tube Serous Adenocarcinoma trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 1 state.
The verdict
NCT02316834, a Early Phase 1 study of Fallopian Tube Serous Adenocarcinoma and High Grade Ovarian Serous Adenocarcinoma, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 4 participants
- Enrollment target
- 6
- Study locations
Study Summary
This pilot early phase I trial studies talazoparib to determine if certain characteristics of the deoxyribonucleic acid (DNA) affect how the disease responds to therapy in patients with ovarian, fallopian tube, or primary peritoneal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Studying samples of tissue in the laboratory from patients receiving talazoparib may help doctors learn more about the effects of talazoparib on cells and may help doctors understand how well patients respond to treatment.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG BMN 673
Study Locations (6)
Texas
- M D Anderson Cancer Center - Houston
- The Woman's Hospital of Texas - Houston
- MD Anderson Regional Care Center-Katy - Houston
- MD Anderson Regional Care Center-Bay Area - Nassau Bay
- MD Anderson Regional Care Center-Sugar Land - Sugar Land
- MD Anderson Regional Care Center-The Woodlands - The Woodlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-06-02 |
| Est. Completion | 2022-01-14 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02316834
The ClinicalTrials.gov registry entry for NCT02316834 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 541-participant average among 8 other Fallopian Tube Serous Adenocarcinoma trials with a reported enrollment target (99% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Fallopian Tube Serous Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02316834 reports 6 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02316834 about?
NCT02316834 is a clinical study titled "Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". This pilot early phase I trial studies talazoparib to determine if certain characteristics of the deoxyribonucleic acid (DNA) affect how the disease responds to therapy in patients with ovarian, fallopian tube, or primary peritoneal cancer that has spread to other places in the body and usually cann...
What is the current status of trial NCT02316834?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2015-06-02. Estimated completion is 2022-01-14.
What conditions does trial NCT02316834 study?
This clinical trial studies the following conditions: Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7.
What interventions are being tested in trial NCT02316834?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), BMN 673 (DRUG).
Who is sponsoring clinical trial NCT02316834?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02316834 being conducted?
This trial has 6 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Serous Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
RECRUITING · Early Phase 1
-
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
RECRUITING · Phase 2
-
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
ACTIVE NOT RECRUITING · Phase 3
-
MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Fallopian Tube Serous Adenocarcinoma
All registered trials for this condition
High Grade Ovarian Serous Adenocarcinoma
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.